did doc carter compare heb to ge here, he has a point re patents=$$$
New Drug Compounds Have Potential to Become the First Broad Spectrum
Treatment
for CFS, HIV and Hep B Infections
PHILADELPHIA, May 21 /PRNewswire/ -- HEMISPHERx Biopharma, Inc.
(Nasdaq: HEMX) announced today the receipt of the 300th patent to
which HEMX has exclusive rights in the area of treating devastating
chronic viral diseases including chronic fatigue syndrome (CFS),
hepatitis B (hep B) and HIV infections.
Termed Oragen(TM) drugs, the compounds are low molecular weight RNA
designer drugs which the Company believes have the potential to
become the first oral, broad-spectrum treatment for various major
viral diseases such as CFS, HIV and hep B infections. In some parts
of the world, more than 20% of the populations are infected with
these diseases. Results from in vitro studies conducted in
collaboration with the National Institute of Allergy and Infectious
Diseases, as well as the National Cancer Institute, indicate that the
Oragen product may have broad-spectrum activities. Oragen drugs can
potentially be engineered to trigger specific responses in immune
cells based on in vitro tests.
The patent recently issued to Temple University from the United
States patent office entitled "Dual action oligoadenylate antiviral
derivatives" is part of the HEMX licensing alliance with Temple
University. The Company focus is on both novel antiviral strategies
as well as developing therapeutics to rearm the body's immune system,
often defective in chronic viral diseases such as hep B, HIV and CFS.
In commenting on the patented technology, HEMX's CEO, Dr. William
Carter, stated: "This exceptionally innovative drug discovery program
produced new drug products which carries multiple payloads needed to
address the chronic infection -- namely, an antiviral warhead and an
immune enhancement device."
HEMX now holds one of the very largest patent portfolios in the
entire biopharmaceutical sector. In commenting on the Company's
expanding patent portfolio breadth and depth, Dr. Carter said:
"Perhaps few of us remember that the most highly valued company in
the world, G.E., with a market capitalization of $180 billion, had
its inception and growth because of the vast patent estate developed
by one man, Dr. Thomas Edison. During his lifetime, he set the U.S.
record of 1,250 patents. I feel his unique career is a powerful
model for how to build a multinational company in the competitive
global marketplace we now face in pharmaceutical development for
untreatable chronic epidemic diseases. These diseases can destroy
not only human health but potentially ruin entire national economies.
"
HEMISPHERx is a biopharmaceutical company engaged in the manufacture
and global clinical development of new drug entities in the nucleic
acid (NA) class for chronic viral disease and disorders of the immune
system.
HEMX is working with regulatory agencies, physicians and its
customers to help ensure that epidemic diseases are prevented,
managed and cured with maximum benefit and minimum costs to patients
and society.
HEMISPHERx corporate web site is www.hemispherx.com SOURCE
HEMISPHERx Biopharma Inc.
|
